GSK to buy Canada's 35Pharma for $950 million
I'm PortAI, I can summarize articles.
GSK has agreed to acquire Canadian biopharmaceutical company 35Pharma for $950 million. This acquisition, aimed at enhancing GSK's respiratory portfolio, includes 35Pharma's drug for pulmonary hypertension. This marks GSK's second major acquisition under CEO Luke Miels, following a $2.2 billion deal for RAPT Therapeutics in January. Additionally, GSK recently secured a $1 billion deal for rights to develop two RNA therapies for kidney diseases.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments